Currently, there are 48.08M common shares owned by the public and among those 38.96M shares have been available to trade.
The company’s stock has a 5-day price change of -6.35% and 17.22% over the past three months. BCAB shares are trading -28.05% year to date (YTD), with the 12-month market performance down to -30.59% lower. It has a 12-month low price of $1.14 and touched a high of $4.02 over the same period. BCAB has an average intraday trading volume of 904.15K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.73%, 9.00%, and -18.27% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of BioAtla Inc (NASDAQ: BCAB) shares accounts for 45.95% of the company’s 48.08M shares outstanding.
It has a market capitalization of $85.56M and a beta (3y monthly) value of 1.05. The earnings-per-share (ttm) stands at -$2.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.88% over the week and 11.31% over the month.
Earnings per share for the fiscal year are expected to increase by 39.29%, and 13.29% over the next financial year.
Looking at the support for the BCAB, a number of firms have released research notes about the stock. JMP Securities stated their Mkt Outperform rating for the stock in a research note on September 15, 2022, with the firm’s price target at $17. Credit Suisse coverage for the BioAtla Inc (BCAB) stock in a research note released on May 05, 2022 offered a Neutral rating with a price target of $5. H.C. Wainwright was of a view on March 21, 2022 that the stock is Buy, while BTIG Research gave the stock Buy rating on October 15, 2021, issuing a price target of $68. ROTH Capital on their part issued Buy rating on June 28, 2021.
